CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of a specific neoadjuvant therapeutic regimen for patients with HER2-overexpressing localized breast cancer, and integrate this information into treatment decision-making.
  • Evaluate published research data to guide the selection and duration of adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer, incorporating existing and recently approved targeted agents and regimens.
  • Design an optimal approach to the clinical care of patients with HER2-positive breast cancer and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other factors.
  • Recognize common and rare side effects associated with existing and recently approved anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
  • Assess ongoing clinical studies evaluating novel agents and treatment strategies under development for HER2-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY AND MODERATOR — The following faculty reported relevant financial relationships with ineligible entities:
  
  Faculty
  
  Carey K Anders, MD
  Professor of Medicine
  Medical Director of the Duke Center of Brain and Spine Metastases
  Duke Cancer Institute
  Durham, North Carolina
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Athenex, Eisai Inc, Elucida Oncology Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Novartis, Seagen Inc; Contracted Research: G1 Therapeutics Inc, Lilly, Merck, Nektar, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Tesaro, A GSK Company, The Zion Pharma; Royalties: Jones and Bartlett Learning.
  
  Virginia F Borges, MD, MMSc
  Professor of Medicine with Tenure
  Robert F and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer Research
  Deputy Head, Division of Medical Oncology
  Director, Breast Cancer Research Program and
  Young Women’s Breast Cancer Translational Program
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Consulting Agreement: Seagen Inc; Contracted Research: Agendia Inc, AstraZeneca Pharmaceuticals LP, Merck, Pfizer Inc, Seagen Inc.
  
  Sara Hurvitz, MD
  Professor of Medicine
  David Geffen School of Medicine at UCLA
  Director, Breast Cancer Clinical Research Program
  Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
  Santa Monica, California
  
  Contracted Research Paid to Institution: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CytomX Therapeutics, Daiichi Sankyo Inc, Dignitana AB, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Immunomedics Inc, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Sanofi Genzyme, Seagen Inc, Zymeworks Inc.
  
  Ian E Krop, MD, PhD
  Associate Chief, Division of Breast Oncology
  Dana-Farber Cancer Institute
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celltrion, Context Therapeutics, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Seagen Inc, Taiho Oncology Inc; Contracted Research: Genentech, a member of the Roche Group, MacroGenics Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Merck, Novartis.
  
  Moderator
  
  Lisa Carey, MD 
  Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research
  Deputy Director of Clinical Sciences
  Lineberger Comprehensive Cancer Center
  University of North Carolina
  Chapel Hill, North Carolina
  
  No relevant conflicts of interest to disclose.
  
  

  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Puma Biotechnology Inc and Seagen Inc.
  
  Release date: January 2022
  Expiration date: January 2023